[go: up one dir, main page]

AR109075A1 - Derivados de etinilo - Google Patents

Derivados de etinilo

Info

Publication number
AR109075A1
AR109075A1 ARP170101987A ARP170101987A AR109075A1 AR 109075 A1 AR109075 A1 AR 109075A1 AR P170101987 A ARP170101987 A AR P170101987A AR P170101987 A ARP170101987 A AR P170101987A AR 109075 A1 AR109075 A1 AR 109075A1
Authority
AR
Argentina
Prior art keywords
compounds
ethylene derivatives
salt
emesis
neuroprotection
Prior art date
Application number
ARP170101987A
Other languages
English (en)
Inventor
Fionn Ohara
Daniel Rueher
Antonio Ricci
Georg Jaeschke
Barbara Biemans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR109075A1 publication Critical patent/AR109075A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a compuestos de fórmulas (1) y (2), o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o estereoisómero correspondiente de los mismos. Los compuestos pueden utilizarse en el tratamiento de la enfermedad de Parkinson, la ansiedad, la emesis, el trastorno obsesivo-compulsivo, el autismo, la neuroprotección, el cáncer, la depresión y la diabetes de tipo 2.
ARP170101987A 2016-07-18 2017-07-17 Derivados de etinilo AR109075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16179837 2016-07-18

Publications (1)

Publication Number Publication Date
AR109075A1 true AR109075A1 (es) 2018-10-24

Family

ID=56418435

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101987A AR109075A1 (es) 2016-07-18 2017-07-17 Derivados de etinilo

Country Status (31)

Country Link
US (3) US20190144458A1 (es)
EP (1) EP3484889B1 (es)
JP (1) JP6936305B2 (es)
KR (1) KR20190026805A (es)
CN (1) CN109476671B (es)
AR (1) AR109075A1 (es)
AU (1) AU2017299083B2 (es)
BR (1) BR112019000314A2 (es)
CA (1) CA3030788A1 (es)
CL (1) CL2019000045A1 (es)
CO (1) CO2018013824A2 (es)
CR (1) CR20190014A (es)
DK (1) DK3484889T3 (es)
ES (1) ES2826389T3 (es)
HR (1) HRP20201615T1 (es)
HU (1) HUE051006T2 (es)
IL (1) IL263884A (es)
LT (1) LT3484889T (es)
MA (1) MA45665B1 (es)
MX (1) MX376249B (es)
PE (1) PE20190382A1 (es)
PH (1) PH12019500119A1 (es)
PL (1) PL3484889T3 (es)
PT (1) PT3484889T (es)
RS (1) RS60908B1 (es)
RU (1) RU2745068C2 (es)
SG (1) SG11201811829QA (es)
SI (1) SI3484889T1 (es)
TW (1) TWI729169B (es)
WO (1) WO2018015235A1 (es)
ZA (1) ZA201900113B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42442B1 (fr) 2015-07-15 2019-07-31 Hoffmann La Roche Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
US11515154B2 (en) * 2020-10-27 2022-11-29 Applied Materials, Inc. Selective deposition of a passivation film

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569915A4 (en) * 2002-12-04 2007-07-11 Merck & Co Inc SPIROCYCLIC UREA, COMPOSITIONS CONTAINING THESE COMPOUNDS AND METHOD OF USE
EP1891075B1 (en) 2005-05-24 2011-10-19 Merck Serono SA Tricyclic spiro derivatives as crth2 modulators
US7998961B2 (en) 2006-08-31 2011-08-16 Schering Corporation Hydantoin derivatives useful as antibacterial agents
MX2009013169A (es) 2007-06-03 2010-04-30 Univ Vanderbilt Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos.
BR112012004919A2 (pt) 2009-09-04 2019-09-24 Univ Vanderbilt potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
PL2702051T3 (pl) 2011-04-26 2015-08-31 Hoffmann La Roche Pochodne etynylu jako pozytywne allosteryczne modulatory mglur5
PH12013501928A1 (en) 2011-04-26 2013-11-25 Hoffmann La Roche Pyrazolidin-3-one derivatives
CA2837312A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
ES2553449T3 (es) * 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
ES2600133T3 (es) 2012-07-17 2017-02-07 F. Hoffmann-La Roche Ag Derivados de ariletinilo
MY171517A (en) 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
UA114934C2 (uk) 2012-10-18 2017-08-28 Ф. Хоффманн-Ля Рош Аг Похідне етинілу як модулятор активності метаботропного глутаматного рецептора підтипу 5
WO2014124560A1 (en) 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Mglur regulators
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
PL3049409T3 (pl) * 2013-09-25 2017-09-29 F.Hoffmann-La Roche Ag Pochodne etynylowe
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
EA029261B1 (ru) 2014-02-25 2018-02-28 Ф. Хоффманн-Ля Рош Аг Производные этинила
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN107207481B (zh) 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物
MA42442B1 (fr) * 2015-07-15 2019-07-31 Hoffmann La Roche Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
US10391998B2 (en) 2016-11-16 2019-08-27 Ford Global Technologies, Llc Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness

Also Published As

Publication number Publication date
DK3484889T3 (da) 2020-10-26
MX2019000442A (es) 2019-06-20
CR20190014A (es) 2019-03-04
SI3484889T1 (sl) 2020-11-30
PL3484889T3 (pl) 2020-12-28
RU2745068C2 (ru) 2021-03-18
EP3484889A1 (en) 2019-05-22
JP6936305B2 (ja) 2021-09-15
TWI729169B (zh) 2021-06-01
CN109476671A (zh) 2019-03-15
RU2019102757A (ru) 2020-08-18
CO2018013824A2 (es) 2018-12-28
PT3484889T (pt) 2020-10-15
AU2017299083A1 (en) 2019-01-24
CN109476671B (zh) 2021-09-24
RS60908B1 (sr) 2020-11-30
JP2019521158A (ja) 2019-07-25
CL2019000045A1 (es) 2019-06-07
PH12019500119A1 (en) 2019-12-11
HRP20201615T1 (hr) 2020-12-11
MA45665B1 (fr) 2020-11-30
US20220127275A1 (en) 2022-04-28
LT3484889T (lt) 2020-11-10
BR112019000314A2 (pt) 2019-04-16
ES2826389T3 (es) 2021-05-18
SG11201811829QA (en) 2019-02-27
AU2017299083B2 (en) 2021-06-24
US20190144458A1 (en) 2019-05-16
MX376249B (es) 2025-03-07
TW201805287A (zh) 2018-02-16
ZA201900113B (en) 2019-09-25
US12145940B2 (en) 2024-11-19
KR20190026805A (ko) 2019-03-13
WO2018015235A1 (en) 2018-01-25
HUE051006T2 (hu) 2021-01-28
IL263884A (en) 2019-01-31
RU2019102757A3 (es) 2020-08-18
EP3484889B1 (en) 2020-08-19
US20200255440A1 (en) 2020-08-13
CA3030788A1 (en) 2018-01-25
PE20190382A1 (es) 2019-03-08
US11242349B2 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
CL2018000036A1 (es) Derivados etinilo
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CO2018002060A2 (es) Compuestos farmacéuticos
AR099047A1 (es) Derivados etinilo
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
AR093042A1 (es) Derivados de etinilo
CO2018013824A2 (es) Derivados de etinilo
AR105662A1 (es) Derivados de piridina y de pirimidina como inhibidores del eaat3
AR104863A1 (es) Derivados imidazol
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
AR099300A1 (es) Hexahidrofuropirroles como inhibidores de pde1
AR105327A1 (es) Derivados de imidazol
AR103952A1 (es) Derivados de pirimidina-diona
CL2017002651A1 (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer
AR107490A1 (es) Derivados de pirazol-piridina como inhibidores de eaat3
AR092097A1 (es) Derivados de ariletinilo
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure